Mediwound Ltd. MDWD
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $16.96M, -16.1% YoY · Filed Mar 5, 2026
Mediwound Ltd. (MDWD) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $17.0 million and a net loss of $23.9 million. Free cash flow was -$21.6 million. As of Dec 31, 2025 it held $4.8 million in cash and investments and $8.2 million in total debt.
Revenue
$16.96M
-16.1% vs prior year
Net income
$-23.88M
+21.0% vs prior year
Operating cash flow
$-16.12M
-18.3% vs prior year
Free cash flow
$-21.63M
-8.7% vs prior year
EPS
$-2.10
+30.7% vs prior year
Dividend per share
None
Shares outstanding
12.84M
+18.9% vs prior year
Net cash
$-3.35M
FY 2025
Operating margin
-149.0%
FY 2025
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- MDWD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Yavne, Israel
- SEC filer status
- Accelerated filer
- SEC CIK
- 1593984
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $17.0M | $20.2M | $18.7M | $26.5M | $23.8M |
| Operating income | -$25.3M | -$19.4M | -$15.3M | -$8.3M | -$11.2M |
| Net income | -$23.9M | -$30.2M | -$6.7M | -$19.6M | -$13.6M |
| Diluted EPS | -$2.10 | -$3.03 | -$0.75 | -$3.93 | — |
| Operating cash flow | -$16.1M | -$13.6M | -$10.5M | -$11.9M | -$8.9M |
| Free cash flow | -$21.6M | -$19.9M | -$16.9M | -$12.4M | -$9.4M |
| Total assets | $86.3M | $73.5M | $66.5M | $50.0M | $19.7M |
| Total liabilities | $42.6M | $42.3M | $34.9M | $39.1M | $24.3M |
| Stockholders' equity | $43.6M | $31.2M | $31.6M | $10.9M | -$4.6M |
| Cash and investments | $4.8M | $9.2M | $11.9M | $33.9M | $11.0M |
| Total debt | $8.2M | $6.5M | $6.3M | $846,000 | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | May 27, 2026 | May 27, 2026 |
| 6-K | Current report (foreign issuer) | May 6, 2026 | May 6, 2026 |
| 6-K | Current report (foreign issuer) | Apr 2, 2026 | Apr 2, 2026 |
| 6-K | Current report (foreign issuer) | Mar 30, 2026 | Mar 30, 2026 |
| 20-F | Annual report (foreign issuer) | Mar 5, 2026 | Dec 31, 2025 |
All 395 Mediwound Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.